SRNE Sorrento Therapeutics Inc

Price (delayed)

$8.25

Market cap

$2.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

$2.55B

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made ...

Highlights
The company's gross profit has surged by 62% YoY and by 10% QoQ
The revenue has increased by 44% YoY and by 10% from the previous quarter
SRNE's equity is up by 36% YoY but it is down by 20% QoQ
The EPS rose by 28% YoY but it fell by 23% QoQ
SRNE's quick ratio has dropped by 72% since the previous quarter and by 19% year-on-year
The company's net income fell by 39% QoQ and by 18% YoY

Key stats

What are the main financial stats of SRNE
Market
Shares outstanding
298.1M
Market cap
$2.46B
Enterprise value
$2.55B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.7
Price to sales (P/S)
46.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.91
Earnings
Revenue
$51.02M
EBIT
-$310.86M
EBITDA
-$295.94M
Free cash flow
-$221.08M
Per share
EPS
-$1.14
Free cash flow per share
-$0.76
Book value per share
$0.65
Revenue per share
$0.18
TBVPS
$1.39
Balance sheet
Total assets
$778.92M
Total liabilities
$593.39M
Debt
$164.74M
Equity
$186.17M
Working capital
-$25.19M
Liquidity
Debt to equity
0.88
Current ratio
0.86
Quick ratio
0.74
Net debt/EBITDA
-0.3
Margins
EBITDA margin
-580%
Gross margin
77%
Net margin
-626.4%
Operating margin
-664.6%
Efficiency
Return on assets
-50.5%
Return on equity
-162.2%
Return on invested capital
-70.9%
Return on capital employed
-51.9%
Return on sales
-609.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRNE stock price

How has the Sorrento Therapeutics stock price performed over time
Intraday
2.1%
1 week
4.17%
1 month
-3.06%
1 year
-12.97%
YTD
20.79%
QTD
-14.86%

Financial performance

How have Sorrento Therapeutics's revenue and profit performed over time
Revenue
$51.02M
Gross profit
$39.27M
Operating income
-$339.08M
Net income
-$319.63M
Gross margin
77%
Net margin
-626.4%
Sorrento Therapeutics's operating income has shrunk by 92% YoY and by 18% QoQ
The company's gross profit has surged by 62% YoY and by 10% QoQ
The revenue has increased by 44% YoY and by 10% from the previous quarter
The company's net income fell by 39% QoQ and by 18% YoY

Growth

What is Sorrento Therapeutics's growth rate over time

Valuation

What is Sorrento Therapeutics stock price valuation
P/E
N/A
P/B
12.7
P/S
46.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.91
The EPS rose by 28% YoY but it fell by 23% QoQ
SRNE's price to book (P/B) is 135% more than its 5-year quarterly average of 5.4 and 4.1% more than its last 4 quarters average of 12.2
SRNE's equity is up by 36% YoY but it is down by 20% QoQ
SRNE's price to sales (P/S) is 82% higher than its 5-year quarterly average of 25.7 but 11% lower than its last 4 quarters average of 52.9
The revenue has increased by 44% YoY and by 10% from the previous quarter

Efficiency

How efficient is Sorrento Therapeutics business performance
The return on invested capital has dropped by 59% year-on-year and by 58% since the previous quarter
The ROE rose by 46% YoY but it fell by 30% QoQ
The ROS fell by 31% QoQ but it rose by 10% YoY
The return on assets has declined by 25% since the previous quarter and by 2.2% year-on-year

Dividends

What is SRNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRNE.

Financial health

How did Sorrento Therapeutics financials performed over time
Sorrento Therapeutics's total assets is 31% higher than its total liabilities
SRNE's quick ratio has dropped by 72% since the previous quarter and by 19% year-on-year
The current ratio has plunged by 69% from the previous quarter but it has increased by 43% YoY
Sorrento Therapeutics's debt is 12% lower than its equity
Sorrento Therapeutics's debt to equity has decreased by 45% YoY but it has increased by 31% QoQ
SRNE's equity is up by 36% YoY but it is down by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.